

Clinical Pharmacogenetics Implementation Consortium and Clopidogrel Therapy: 2013 Update

Clinical Pharmacology and Therapeutics

94, 317-323

DOI: [10.1038/clpt.2013.105](https://doi.org/10.1038/clpt.2013.105)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Public Health Genomics Translation Gap: What We Don't Have and Why It Matters. <i>Public Health Genomics</i> , 2012, 15, 132-138.	0.6	12
2	Pharmacogenomic considerations in opioid analgesia. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 73.	0.4	26
3	Genomic Medicine, Precision Medicine, Personalized Medicine: What's in a Name?. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 169-172.	2.3	59
4	An Allele-Specific PCR System for Rapid Detection and Discrimination of the CYP2C19 [∗] 4A, [∗] 4B, and [∗] 17 Alleles. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 783-789.	1.2	17
5	Electronic health record design and implementation for pharmacogenomics: a local perspective. <i>Genetics in Medicine</i> , 2013, 15, 833-841.	1.1	87
6	Integration of genomics into the electronic health record: mapping terra incognita. <i>Genetics in Medicine</i> , 2013, 15, 757-760.	1.1	28
7	Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?. <i>Journal of Human Genetics</i> , 2013, 58, 339-345.	1.1	28
8	Cytochrome P450 3A4 [∗] 22, PPAR- α , and ARNT polymorphisms and clopidogrel response. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 185.	0.8	9
9	Open Access Integrated Therapeutic and Diagnostic Platforms for Personalized Cardiovascular Medicine. <i>Journal of Personalized Medicine</i> , 2013, 3, 203-237.	1.1	16
10	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. <i>Current Drug Metabolism</i> , 2014, 15, 209-217.	0.7	341
11	Health Data Cooperatives – Citizen Empowerment. <i>Methods of Information in Medicine</i> , 2014, 53, 82-86.	0.7	92
12	<i>CYP2C19</i> Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated With Clopidogrel. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 895-902.	5.1	107
13	Pharmacodynamic Pharmacogenomics. , 2014, , 365-383.		4
14	Pharmacogenomics of Clopidogrel. , 2014, , 509-541.		1
15	Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1289-1303.	0.6	4
16	Pilot study: incorporation of pharmacogenetic testing in medication therapy management services. <i>Pharmacogenomics</i> , 2014, 15, 1729-1737.	0.6	13
17	Frequency of CYP450 enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significance. <i>Drug Metabolism and Drug Interactions</i> , 2014, 29, 235-248.	0.3	12
18	Development of a Multiplex and Cost-Effective Genotype Test toward More Personalized Medicine for the Antiplatelet Drug Clopidogrel. <i>International Journal of Molecular Sciences</i> , 2014, 15, 7699-7710.	1.8	5

#	ARTICLE	IF	CITATIONS
19	Implementing Clinical Pharmacogenetics: Point-of-Care and Pre-Emptive Testing. , 2014, , 921-930.		0
20	Pharmacogenomics of antiplatelet drugs. Hematology American Society of Hematology Education Program, 2014, 2014, 343-347.	0.9	3
21	Priority pharmacogenetics for the African continent: focus on CYP450. Pharmacogenomics, 2014, 15, 385-400.	0.6	10
22	World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nature Reviews Cardiology, 2014, 11, 597-606.	6.1	267
23	Aspirin Decreases Systemic Exposure to Clopidogrel Through Modulation of P-Glycoprotein But Does Not Alter Its Antithrombotic Activity. Clinical Pharmacology and Therapeutics, 2014, 95, 608-616.	2.3	26
24	Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes. Drug Metabolism and Disposition, 2014, 42, 1971-1977.	1.7	24
25	<i><sc>CYP</sc>2C19</i> Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?. Pharmacotherapy, 2014, 34, 703-718.	1.2	104
26	Use of Contemporary Genetics in Cardiovascular Diagnosis. Circulation, 2014, 130, 1971-1980.	1.6	7
27	Implementation of pharmacogenetics: The University of Maryland personalized antiplatelet pharmacogenetics program. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 76-84.	0.7	82
28	Emerging Roles for Pharmacists in Clinical Implementation of Pharmacogenomics. Pharmacotherapy, 2014, 34, 1102-1112.	1.2	105
29	Highlights from recent advances in antiplatelet pharmacogenomics. Personalized Medicine, 2014, 11, 135-138.	0.8	0
30	Pharmacogenetics in the Community Pharmacy. Journal of Pharmacy Practice, 2014, 27, 416-419.	0.5	21
31	Perioperative Management of the Patient with a Coronary Artery Stent. Anesthesiology, 2014, 121, 1093-1098.	1.3	8
32	Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics, 2014, 15, 2025-2048.	0.6	21
33	Implementation and utilization of genetic testing in personalized medicine. Pharmacogenomics and Personalized Medicine, 2014, 7, 227.	0.4	63
34	Considerations for rare variants in drug metabolism genes and the clinical implications. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 873-884.	1.5	22
35	Pharmacogenetics in Jewish populations. Drug Metabolism and Drug Interactions, 2014, 29, 221-233.	0.3	14
36	Clinical Interpretation and Implications of Whole-Genome Sequencing. JAMA - Journal of the American Medical Association, 2014, 311, 1035.	3.8	398

#	ARTICLE	IF	CITATIONS
37	Clinically Actionable Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic Testing. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 423-431.	2.3	272
38	Cardiovascular Pharmacogenomics: Expectations and Practical Benefits. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 281-293.	2.3	54
39	Epigenetic primer for diagnostic applications: a window into personalized medicine. <i>Personalized Medicine</i> , 2014, 11, 323-337.	0.8	2
40	PG4KDS: A model for the clinical implementation of preemptive pharmacogenetics. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2014, 166, 45-55.	0.7	221
41	Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia – a randomized, double-blind, double-dummy crossover study. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1058-1066.	1.1	7
42	Pharmacogenomics of oral antiplatelet drugs. <i>Pharmacogenomics</i> , 2014, 15, 509-528.	0.6	10
43	Role of phenotypic and genetic testing in managing clopidogrel therapy. <i>Blood</i> , 2014, 124, 689-699.	0.6	28
44	Clustering of Acute and Subacute Stent Thrombosis Related to the Introduction of Generic Clopidogrel. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 201-208.	1.0	15
45	Analysis of compound heterozygous <i>CYP2C19</i> genotypes to determine <i>cis</i> and <i>trans</i> configurations. <i>Pharmacogenomics</i> , 2014, 15, 1197-1205.	0.6	9
46	Clopidogrel dose adjustment after outpatient screening for <i>CYP2C19</i> variant alleles: a pilot study. <i>Pharmacogenomics</i> , 2014, 15, 915-923.	0.6	9
47	Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations. <i>Pharmacotherapy</i> , 2014, 34, 973-990.	1.2	2
48	Voriconazole pharmacokinetics and exposure-response relationships: Assessing the links between exposure, efficacy and toxicity. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 183-193.	1.1	77
49	Clinical pharmacogenetics implementation: Approaches, successes, and challenges. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2014, 166, 56-67.	0.7	162
50	Prioritizing Genomic Applications for Action by Level of Evidence: A Horizon-Scanning Method. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 394-402.	2.3	53
51	Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 307-313.	2.3	49
52	Chasing Mendel: five questions for personalized medicine. <i>Journal of Physiology</i> , 2014, 592, 2381-2388.	1.3	30
53	Towards a Molecular Systems Model of Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2014, 16, 488.	1.3	19
54	Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in <i>CYP2C19</i> poor metabolizers. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 865-873.	1.0	31

#	ARTICLE	IF	CITATIONS
55	“East Asian Paradox” Challenge for the Current Antiplatelet Strategy of “One-Guideline-Fits-All Races” in Acute Coronary Syndrome. <i>Current Cardiology Reports</i> , 2014, 16, 485.	1.3	136
56	Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 723-734.	1.4	0
57	CYP450 and Ethnicity. , 2014, , 323-340.		5
58	Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2014, 60, 993-1001.	0.6	36
59	Surveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal Genomics. <i>Yearbook of Medical Informatics</i> , 2014, 23, 199-205.	0.8	18
60	Personalized medicine: importance of clinical interpretative skills for real-world patient care. <i>Personalized Medicine</i> , 2014, 11, 395-408.	0.8	0
61	Genotype-guided use of oral antithrombotic therapy: a pharmacoeconomic perspective. <i>Personalized Medicine</i> , 2014, 11, 223-235.	0.8	10
62	Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. <i>Genetical Research</i> , 2015, 97, e13.	0.3	48
63	PHILO““ Ensuring Trial Results Are Not Lost in Translation “”. <i>Circulation Journal</i> , 2015, 79, 2326-2328.	0.7	2
64	EHR based Genetic Testing Knowledge Base (iGTKB) Development. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, S3.	1.5	4
65	Academic and professional pharmacy education: a pharmacogenomics certificate training program. <i>Personalized Medicine</i> , 2015, 12, 563-573.	0.8	23
66	Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 692-697.	1.9	36
67	Genetic variation in the human cytochrome P450 supergene family. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 584-594.	0.7	127
68	A survey on the awareness and attitude of pharmacists and doctors towards the application of pharmacogenomics and its challenges in <sc>Q</sc>atar. <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 703-709.	0.9	49
69	CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 609-617.	0.7	14
70	Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances. <i>Biopharmaceutics and Drug Disposition</i> , 2015, 36, 636-643.	1.1	7
71	Three POCT Molecular Applications. <i>Point of Care</i> , 2015, 14, 95-98.	0.5	1
72	Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1421.	0.9	14

#	ARTICLE	IF	CITATIONS
73	INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. <i>Rational Pharmacotherapy in Cardiology</i> , 2015, 11, 344-354.	0.3	0
74	Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. <i>Pharmacogenomics and Personalized Medicine</i> , 2015, 8, 43.	0.4	27
75	Financial Analysis of <i>CYP2C19</i> Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 552-557.	0.5	21
76	Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related <i>CYP2C19</i> Genotyping in China: A Novel Approach. <i>PLoS ONE</i> , 2015, 10, e0134174.	1.1	4
78	Individualised dual antiplatelet therapy in a patient with short bowel syndrome after acute myocardial infarction with coronary artery stenting. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014205227.	0.2	5
79	Integration of Genomics in Primary Care. <i>American Journal of Medicine</i> , 2015, 128, 1251.e1-1251.e5.	0.6	36
80	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and <i>CYP2C19</i> Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 127-134.	2.3	739
82	Correlation of <i>CYP2C19</i> genotype with plasma voriconazole levels: a preliminary retrospective study in Indians. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 925-930.	1.0	18
83	Joint effects of <i>CYP2C19*2</i> and smoking status on clopidogrel responsiveness in patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2015, 180, 196-198.	0.8	8
84	Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 147-163.	0.3	6
85	Implementation of a pharmacogenetic management service for postmyocardial infarction care in a community pharmacy. <i>Personalized Medicine</i> , 2015, 12, 319-325.	0.8	15
86	Drug resistance and secondary treatment of ischaemic stroke: The genetic component of the response to acetylsalicylic acid and clopidogrel. <i>Neurologia (English Edition)</i> , 2015, 30, 566-573.	0.2	4
87	<i>CYP2C19</i> Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study. <i>Journal of the American Heart Association</i> , 2015, 4, e001652.	1.6	44
88	Pharmacogenomics and cardiology: improving treatment with existing drugs. <i>Pharmacogenomics</i> , 2015, 16, 1223-1226.	0.6	1
89	Genetic factors affecting drug disposition in Asian cancer patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1879-1892.	1.5	21
90	Pharmacogenetic Considerations in the Elderly Patient. <i>The Consultant Pharmacist</i> , 2015, 30, 228-239.	0.4	1
91	Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians. <i>Journal of Biomedical Informatics</i> , 2015, 55, 249-259.	2.5	27
92	Effect of high-dose clopidogrel according to <i>CYP2C19*2</i> genotype in patients undergoing percutaneous coronary intervention—a systematic review and meta-analysis. <i>Thrombosis Research</i> , 2015, 135, 449-458.	0.8	39

#	ARTICLE	IF	CITATIONS
93	Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 771-779.	0.9	21
94	Prevalence and significance of <i>CYP2C19*2</i> and <i>CYP2C19*17</i> alleles in a New Zealand acute coronary syndrome population. <i>Internal Medicine Journal</i> , 2015, 45, 537-545.	0.5	6
95	Managing the acute coronary syndrome patient: Evidence based recommendations for anti-platelet therapy. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2015, 44, 141-149.	0.8	10
96	Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice. <i>International Journal of Cardiology</i> , 2015, 184, 772-795.	0.8	15
97	Differential Impact of Selective Serotonin Reuptake Inhibitors on Platelet Response to Clopidogrel: A Randomized, Double-Blind, Crossover Trial. <i>Pharmacotherapy</i> , 2015, 35, 140-147.	1.2	10
98	Novel Anti-platelet Agents in Acute Coronary Syndrome: Mechanisms of Action and Opportunities to Tailor Therapy. <i>Current Atherosclerosis Reports</i> , 2015, 17, 501.	2.0	3
99	Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 650-658.	2.3	70
100	Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1223-1235.	1.6	41
101	Clinical implications of neuropharmacogenetics. <i>Revue Neurologique</i> , 2015, 171, 482-497.	0.6	3
102	Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 411-421.	1.3	4
103	Pharmacogenomics in cardiology – genetics and drug response: 10 years of progress. <i>Future Cardiology</i> , 2015, 11, 281-286.	0.5	7
104	Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. <i>Open Heart</i> , 2015, 2, e000248.	0.9	66
105	A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI. <i>Indian Heart Journal</i> , 2015, 67, 114-121.	0.2	8
106	The pharmacogenetic control of antiplatelet response: candidate genes and <i>CYP2C19</i> . <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1599-1617.	1.5	22
107	CYP2C19 LOF alleles confer no risk for HTPR but higher risk for recurrent ischemic events in clopidogrel treated elderly ACS patients. <i>International Journal of Cardiology</i> , 2015, 189, 225-227.	0.8	4
108	Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole. <i>Current Fungal Infection Reports</i> , 2015, 9, 74-87.	0.9	38
109	Genotype-based clinical trials in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2015, 12, 475-487.	6.1	37
110	Implementation and evaluation of a <i>CYP2C19</i> genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. <i>Pharmacogenomics</i> , 2015, 16, 303-313.	0.6	32

#	ARTICLE	IF	CITATIONS
111	Clinical application of pharmacogenetics: focusing on practical issues. <i>Pharmacogenomics</i> , 2015, 16, 1733-1741.	0.6	14
112	The <i>CYP2C19</i> Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with <i>CYP2C19*35</i> and <i>CYP2C19*2</i> Alleles. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1226-1235.	1.7	23
113	Clinician perspectives on using pharmacogenomics in clinical practice. <i>Personalized Medicine</i> , 2015, 12, 339-347.	0.8	67
114	Comprehensive Evaluation for Substrate Selectivity of Cynomolgus Monkey Cytochrome P450 2C9, a New Efavirenz Oxidase. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1119-1122.	1.7	12
115	Will personalized drugs for cardiovascular disease become an option? â€œ Defining â€œEvidence-based personalized medicineâ€™ for its implementation and future use. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2549-2552.	0.9	5
116	Time-Dependent Inhibition of <i>CYP2C19</i> by Isoquinoline Alkaloids: In Vitro and In Silico Analysis. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1891-1904.	1.7	7
117	Genetics of Cardiovascular Disease. , 2015, , 117-127.		0
118	Pharmacogenomics of Hypertension and Heart Disease. <i>Current Hypertension Reports</i> , 2015, 17, 586.	1.5	18
120	Prevention of Cardiovascular Diseases. , 2015, , .		1
121	Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 89-106.	4.2	442
122	La resistencia en el tratamiento secundario del ictus isquÃ©mico, el componente genÃ©tico en la respuesta a Ã¡cido acetilsalicÃ©ico y clopidogrel. <i>NeurologÃ­a</i> , 2015, 30, 566-573.	0.3	6
123	Is personalized medicine a dream or a reality?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015, 52, 1-11.	2.7	24
125	Relevance of Personalized Health Care in Patients with Arterial Hypertension: Where are we now?. , 2016, , .		1
126	Correlation Between the <i>CYP2C19</i> Phenotype Status and the Results of Three Different Platelet Function Tests in Cardiovascular Disease Patients Receiving Antiplatelet Therapy: An Emphasis on Newly Introduced Platelet Function Analyzer-200 P2Y Test. <i>Annals of Laboratory Medicine</i> , 2016, 36, 42-48.	1.2	15
127	The Role of Genetics in Acute Coronary Syndrome. , 2016, , 25-55.		0
128	Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2016, 115, 979-992.	1.8	14
129	Pharmacogenetics and Pharmacogenomics. , 2016, , 121-137.		5
130	Comparison of genome sequencing and clinical genotyping for pharmacogenes. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 380-388.	2.3	46

#	ARTICLE	IF	CITATIONS
131	Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 28-39.	0.7	21
132	Pharmacogenetics in Cardiovascular Medicine. <i>Current Genetic Medicine Reports</i> , 2016, 4, 119-129.	1.9	9
133	Pharmacogenomics. <i>Journal of Infusion Nursing</i> , 2016, 39, 139-148.	1.2	1
134	Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 232-236.	0.8	62
135	Physician response to implementation of genotype-tailored antiplatelet therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 67-74.	2.3	47
136	The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 401-404.	2.3	9
137	Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 282-293.	1.9	17
138	History repeats itself: the family medication history and pharmacogenomics. <i>Pharmacogenomics</i> , 2016, 17, 669-678.	0.6	10
139	Evidence and resources to implement pharmacogenetic knowledge for precision medicine. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1977-1985.	0.5	79
140	Characterization of Three CYP2C19 Gene Variants by MassARRAY and Point of Care Techniques: Experience from a Czech Centre. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 99-107.	1.0	4
141	Merging Electronic Health Record Data and Genomics for Cardiovascular Research. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 193-202.	5.1	20
142	Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome. <i>Pharmacogenomics</i> , 2016, 17, 701-713.	0.6	28
143	Navigating pleiotropy in precision medicine: pharmacogenes from trauma to behavioral health. <i>Pharmacogenomics</i> , 2016, 17, 499-505.	0.6	7
144	Simultaneous subacute coronary artery stent thrombosis in a carrier of two CYP2C19 loss-of-function polymorphisms (*2/*3). <i>International Journal of Cardiology</i> , 2016, 212, 148-150.	0.8	5
145	Proton pump inhibitors and other disease-based factors in the recurrence of adverse cardiovascular events following percutaneous coronary angiography: A long-term cohort. <i>Indian Journal of Gastroenterology</i> , 2016, 35, 117-122.	0.7	7
146	Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome. <i>Journal of Genetics</i> , 2016, 95, 231-237.	0.4	11
147	Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients. <i>Genetic Testing and Molecular Biomarkers</i> , 2016, 20, 609-615.	0.3	1
148	Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1832-1838.	1.7	16

#	ARTICLE	IF	CITATIONS
149	Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent. <i>International Journal of Cardiology</i> , 2016, 225, 289-295.	0.8	48
150	Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1195-1204.	0.8	16
151	Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges. <i>Clinical and Translational Science</i> , 2016, 9, 233-245.	1.5	72
152	Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty. <i>Pharmacogenomics</i> , 2016, 17, 1327-1338.	0.6	11
153	Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. <i>Clinical and Translational Science</i> , 2016, 9, 23-28.	1.5	32
154	Clopidogrel pharmacogenetics: from evidence to implementation. <i>Future Cardiology</i> , 2016, 12, 511-514.	0.5	3
155	Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands. <i>Netherlands Heart Journal</i> , 2016, 24, 589-599.	0.3	38
156	Effect of antituberculosis treatment on CYP2C19 enzyme activity in genetically polymorphic South Indian Tamilian population. <i>Fundamental and Clinical Pharmacology</i> , 2016, 30, 607-615.	1.0	0
157	Implementation of a multidisciplinary pharmacogenomics clinic in a community health system. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1956-1966.	0.5	101
158	Implementation of inpatient models of pharmacogenetics programs. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1944-1954.	0.5	34
159	Integrating pharmacogenomics into electronic health records with clinical decision support. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1967-1976.	0.5	118
160	The Paradox of Smoking and Clopidogrel Effect—“Dr Jekyll or Mr Hyde?”. <i>Circulation Journal</i> , 2016, 80, 1529-1531.	0.7	2
161	Association between CYP3A5 polymorphisms and the risk of adverse events in patients undergoing clopidogrel therapy: Meta-analysis. <i>Thrombosis Research</i> , 2016, 147, 1-6.	0.8	1
162	Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 593-603.	1.0	20
163	Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study. <i>Journal of the Chinese Medical Association</i> , 2016, 79, 521-530.	0.6	38
165	Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. <i>Pharmacogenomics</i> , 2016, 17, 1775-1784.	0.6	13
166	The impact of P2Y12 promoter DNA methylation on the recurrence of ischemic events in Chinese patients with ischemic cerebrovascular disease. <i>Scientific Reports</i> , 2016, 6, 34570.	1.6	14
167	Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets. <i>Pharmacogenomics</i> , 2016, 17, 1891-1901.	0.6	14

#	ARTICLE	IF	CITATIONS
168	Preliminary Data from a Study on Polymorphism RS4244285 of P4502c19 Cytochrome Gene in Patients with Acute Coronary Syndrome, Undergoing Treatment with Dual Antiplatelet Therapy With Clopidogrel and Aspirin. <i>Journal of Biomedical and Clinical Research</i> , 2016, 9, 65-71.	0.1	0
169	High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial. <i>Acta Cardiologica</i> , 2016, 71, 309-316.	0.3	20
170	Current status of personalized medicine based on pharmacogenetics in cardiovascular medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 5-8.	0.4	1
171	Pharmacogenetics in Oral Antithrombotic Therapy. <i>Clinics in Laboratory Medicine</i> , 2016, 36, 461-472.	0.7	8
172	Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe. <i>International Journal of Cardiology</i> , 2016, 220, 488-495.	0.8	8
173	Association Between <i>CYP2C19</i> Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 70.	3.8	276
174	Evidence for extensive pleiotropy among pharmacogenes. <i>Pharmacogenomics</i> , 2016, 17, 853-866.	0.6	10
175	Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) – study protocol for a pragmatic randomized controlled trial. <i>BMC Family Practice</i> , 2016, 17, 49.	2.9	14
176	Comparison of a rapid point-of-care and two laboratory-based CYP2C19*2 genotyping assays for personalisation of antiplatelet therapy. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 414-420.	1.0	14
177	Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program. <i>Future Cardiology</i> , 2016, 12, 405-418.	0.5	9
178	Dual antiplatelet therapy, drug-eluting stents and bioresorbable vascular scaffolds: Evolutionary perspectives. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 909-919.	0.7	5
179	Metabolic Interaction Potential between Clopidogrel and Sulfonylurea Antidiabetic Agents: Effects on Clopidogrel Bioactivation. <i>Pharmacology</i> , 2016, 97, 18-24.	0.9	3
180	Clopidogrel Response Variability. <i>Journal of Pharmacy Practice</i> , 2016, 29, 26-34.	0.5	24
181	Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 482-486.	2.0	37
182	Cardiovascular Pharmacogenomics – Implications for Patients With CKD. <i>Advances in Chronic Kidney Disease</i> , 2016, 23, 82-90.	0.6	12
183	P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. <i>Pharmacology</i> , 2016, 97, 101-106.	0.9	15
184	Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTEMI-ACS. <i>Platelets</i> , 2016, 27, 440-445.	1.1	22
185	The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. <i>Journal of Medical Economics</i> , 2016, 19, 213-228.	1.0	116

#	ARTICLE	IF	CITATIONS
186	Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2016, 117, 656-663.	0.7	18
187	Physicians'™ attitudes toward pharmacogenetic testing before and after pharmacogenetic education. <i>Personalized Medicine</i> , 2016, 13, 119-127.	0.8	29
188	Cytochrome P450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 61-67.	0.5	47
189	Hypertension pharmacogenomics: in search of personalized treatment approaches. <i>Nature Reviews Nephrology</i> , 2016, 12, 110-122.	4.1	90
190	Impact of New Genomic Technologies on Understanding Adverse Drug Reactions. <i>Clinical Pharmacokinetics</i> , 2016, 55, 419-436.	1.6	13
191	The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 255-265.	0.7	16
192	A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 745-756.	0.6	29
193	Utilization of genetic tests: analysis of gene-specific billing in Medicare claims data. <i>Genetics in Medicine</i> , 2017, 19, 890-899.	1.1	31
194	Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 493-501.	2.3	19
196	Personalized medicine: Genetic risk prediction of drug response. , 2017, 175, 75-90.		47
197	Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx). <i>Therapie</i> , 2017, 72, 257-267.	0.6	25
198	Association of genetic variant and platelet function in patients undergoing neuroendovascular stenting. <i>Postgraduate Medical Journal</i> , 2017, 93, 555-559.	0.9	6
199	Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome. <i>Journal of International Medical Research</i> , 2017, 45, 134-146.	0.4	19
200	Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting. <i>Pharmacogenomics</i> , 2017, 18, 327-335.	0.6	14
201	Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer. <i>Pharmacogenomics</i> , 2017, 18, 601-605.	0.6	7
202	Factors Affecting the Obliteration Rate of Intracranial Aneurysms Treated with a Single Pipeline Embolization Device. <i>World Neurosurgery</i> , 2017, 104, 205-212.	0.7	33
203	The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 754-762.	0.4	6
204	Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 279-284.	0.7	12

#	ARTICLE	IF	CITATIONS
205	Clinical Trial Design in Juvenile Idiopathic Arthritis. <i>Paediatric Drugs</i> , 2017, 19, 379-389.	1.3	17
206	The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, Tj ETQq1 1 0.78434 rgBT 48verlock	1.0	13
207	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 201-209.	0.7	23
208	Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 190-196.	0.7	42
209	Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients. <i>Molecular Genetics & Genomic Medicine</i> , 2017, 5, 269-279.	0.6	30
210	Distribution of CYP2C19 polymorphisms in Mongolian and Han nationals and the choice of specific antiplatelet drugs. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 791-797.	1.0	5
211	Clinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial. <i>Pharmacogenomics</i> , 2017, 18, 835-841.	0.6	6
212	Precision Cardiovascular Medicine: State of Genetic Testing. <i>Mayo Clinic Proceedings</i> , 2017, 92, 642-662.	1.4	49
213	Avoidable drug-gene conflicts and polypharmacy interactions in patients participating in a personalized medicine program. <i>Personalized Medicine</i> , 2017, 14, 221-233.	0.8	10
214	Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 347-355.	1.0	13
215	The use of intravenous tPA for the treatment of severe frostbite. <i>Burns</i> , 2017, 43, 1088-1096.	1.1	28
216	The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. <i>Clinical and Translational Science</i> , 2017, 10, 143-146.	1.5	82
217	Genetic Determinants of P2Y12 Inhibitors and Clinical Implications. <i>Interventional Cardiology Clinics</i> , 2017, 6, 141-149.	0.2	11
218	East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1152-1159.	1.4	8
219	Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease. <i>Clinical Chemistry</i> , 2017, 63, 177-185.	1.5	9
220	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 45-51.	2.3	266
221	Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai. <i>Pharmacogenomics</i> , 2017, 18, 1381-1386.	0.6	20
222	Pharmacogenetics: a general review on progress to date. <i>British Medical Bulletin</i> , 2017, 124, 1-15.	2.7	48

#	ARTICLE	IF	CITATIONS
223	Clinical pharmacogenomics: patient perspectives of pharmacogenomic testing and the incidence of actionable test results in a chronic disease cohort. <i>Personalized Medicine</i> , 2017, 14, 383-388.	0.8	13
224	Association of ABCB1 promoter methylation with aspirin exposure, platelet function, and clinical outcomes in Chinese intracranial artery stenosis patients. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1261-1269.	0.8	12
226	CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. <i>Pharmacogenomics</i> , 2017, 18, 1155-1166.	0.6	31
227	Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents. <i>Pharmacogenomics</i> , 2017, 18, 1225-1239.	0.6	5
228	The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients. <i>Thrombosis Research</i> , 2017, 158, 22-24.	0.8	16
229	An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review. <i>Pharmacogenomics</i> , 2017, 18, 1541-1550.	0.6	24
230	Genome sequencing as a platform for pharmacogenetic genotyping: a pediatric cohort study. <i>Npj Genomic Medicine</i> , 2017, 2, 19.	1.7	41
231	Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers. <i>AAPS Journal</i> , 2017, 19, 1513-1522.	2.2	21
232	Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 581-589.	0.6	7
233	Concepts of Genomics in Kidney Transplantation. <i>Current Transplantation Reports</i> , 2017, 4, 116-123.	0.9	4
234	Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs. <i>Pharmacotherapy</i> , 2017, 37, 1005-1013.	1.2	7
236	Identifying clinically relevant sources of variability: The clopidogrel challenge. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 264-273.	2.3	14
237	Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine. <i>Clinical Pharmacokinetics</i> , 2017, 56, 525-536.	1.6	8
238	Drug Metabolism in Cardiovascular Disease. , 2017, , 139-156.		0
239	Ayurgenomics for stratified medicine: TRISUTRA consortium initiative across ethnically and geographically diverse Indian populations. <i>Journal of Ethnopharmacology</i> , 2017, 197, 274-293.	2.0	38
240	Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 70-70.	21.5	80
241	Acute stent thrombosis after stent-assisted coiling in an intracranial aneurysm patient carrying two reduced-function CYP2C19 alleles. <i>Medicine (United States)</i> , 2017, 96, e8920.	0.4	4
242	Piperidine-Based Fused Biheterocycles. , 2017, , 269-286.		0

#	ARTICLE	IF	CITATIONS
243	Platelets, Haemostasis and Inflammation. Cardiac and Vascular Biology, 2017, , .	0.2	5
244	Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system. Pharmacy Practice, 2017, 15, 946-946.	0.8	6
245	3. Pharmakogenetik In Der Praxis. , 2017, , 218-440.		0
246	2. Pharmakogenetik. , 2017, , 189-217.		0
247	Personalized Medicine in Cardiovascular Disease. , 2017, , 457-471.		1
248	Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives. International Journal of Environmental Research and Public Health, 2017, 14, 301.	1.2	43
249	The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. Cardiology Research and Practice, 2017, 2017, 1-17.	0.5	44
250	CYP2C19<math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:msup><mml:mrow /><mml:mrow><mml:mo>âŽ</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math>2 Polymorphism in Chilean Patients with In-Stent Restenosis Development and Controls. BioMed Research International, 2017, 2017, 1-6.	0.9	5
251	Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines. Annals of Laboratory Medicine, 2017, 37, 180-193.	1.2	15
252	Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. Pharmacogenomics and Personalized Medicine, 2017, Volume 10, 253-259.	0.4	7
253	Prevalence of clinically actionable genotypes and medication exposure of older adults in the community. Pharmacogenomics and Personalized Medicine, 2017, Volume10, 17-27.	0.4	2
254	Recommendations for Clinical CYP2C19 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2018, 20, 269-276.	1.2	131
255	Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 17.	0.4	1
256	Monotherapy with a novel intervenolin derivative, ASâ€1934, is an effective treatment for Helicobacter pylori infection. Helicobacter, 2018, 23, e12470.	1.6	15
257	Genetic Contributions and Personalized Medicine. , 2018, , 3-16.		1
258	Pharmacist-Provided Pharmacogenetic Point-of-Care Testing Consultation Service: A Time and Motion Study. Journal of Pharmacy Technology, 2018, 34, 139-143.	0.5	8
259	Implementation of Genotype-Guided Antiplatelet Therapy. Circulation Genomic and Precision Medicine, 2018, 11, e002118.	1.6	3
260	Genetic Testing in Clinical Settings. American Journal of Kidney Diseases, 2018, 72, 569-581.	2.1	33

#	ARTICLE	IF	CITATIONS
261	Development of a Polymerase Chain Reaction/Ligase Detection Reaction Assay for Detection of <i>CYP2C19</i> Polymorphisms. <i>Genetic Testing and Molecular Biomarkers</i> , 2018, 22, 62-73.	0.3	2
262	Pharmacogenetics and Pharmacogenomics in Cardiovascular Medicine and Surgery. , 2018, , 119-172.		0
263	Multisite Investigation of Strategies for the Implementation of <i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 664-674.	2.3	94
264	Clinical implementation of rapid <i>CYP2C19</i> genotyping to guide antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Translational Medicine</i> , 2018, 16, 92.	1.8	41
265	A pharmacogenetics approach to pain management. <i>Neuropsychopharmacology Reports</i> , 2018, 38, 2-8.	1.1	13
266	Feasibility and implementation of <i>CYP2C19</i> genotyping in patients using antiplatelet therapy. <i>Pharmacogenomics</i> , 2018, 19, 621-628.	0.6	19
267	Clinical Outcomes and Sustainability of Using <i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002069.	1.6	58
268	Role of <i>CYP2C19</i> genotype testing in clinical use of clopidogrel: is it really useful?. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 369-377.	0.6	15
269	A Literature Review of Genetic Markers Conferring Impaired Response to Cardiovascular Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 259-269.	1.0	3
270	<i>CYP2C19</i> Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Pharmacology</i> , 2018, 71, 347-351.	0.8	7
271	Genomics-Guided Antithrombotic Therapy for Acute Coronary Syndromes. , 2018, , 147-161.		0
272	Cardiovascular Pharmacogenetics. , 2018, , 291-307.		0
273	Impact of <i>CYP2C19</i> Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors. <i>American Journal of Therapeutics</i> , 2018, 25, e202-e212.	0.5	12
274	Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 599-618.	2.3	186
275	Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 281-286.	2.3	19
276	Role of genetic testing in patients undergoing percutaneous coronary intervention. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 151-164.	1.3	57
277	Patient Decisions to Receive Secondary Pharmacogenomic Findings and Development of a Multidisciplinary Practice Model to Integrate Results Into Patient Care. <i>Clinical and Translational Science</i> , 2018, 11, 71-76.	1.5	16
278	Multisite Investigation of Outcomes With Implementation of <i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 181-191.	1.1	213

#	ARTICLE	IF	CITATIONS
279	Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula. <i>Annals of Human Biology</i> , 2018, 45, 66-71.	0.4	10
280	Point-of-care companion diagnostic tests for personalizing psychiatric medications: fulfilling an unmet clinical need. <i>Journal of Breath Research</i> , 2018, 12, 017101.	1.5	6
281	Biomarkers of adverse drug reactions. <i>Experimental Biology and Medicine</i> , 2018, 243, 291-299.	1.1	25
282	Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy. <i>Clinical Pharmacokinetics</i> , 2018, 57, 739-748.	1.6	19
283	Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 423-431.	0.8	15
284	Management of antiplatelet therapy in patients undergoing neuroendovascular procedures. <i>Journal of Neurosurgery</i> , 2018, 129, 890-905.	0.9	74
285	Biomarkers: Delivering on the expectation of molecularly driven, quantitative health. <i>Experimental Biology and Medicine</i> , 2018, 243, 313-322.	1.1	13
286	Structural Destabilization of Intramolecular Duplexes Improves the Results of DNA Hybridization Analysis. <i>Biophysics (Russian Federation)</i> , 2018, 63, 880-887.	0.2	0
287	Late stent thrombosis in a patient with <i>CYP2C19*3/*17</i> genotype and clopidogrel high on-treatment platelet reactivity. <i>Pharmacogenomics</i> , 2018, 19, 1151-1157.	0.6	0
289	Building Evidence for Clinical Use of Pharmacogenomics and Reimbursement for Testing. <i>Advances in Molecular Pathology</i> , 2018, 1, 125-134.	0.2	5
290	The potential of genotype-guided antiplatelet therapy: promises and challenges. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 371-377.	0.4	0
291	Relationship Between Pharmacokinetics and Pharmacogenomics and Its Impact on Drug Choice and Dose Regimens. , 2018, , 169-202.		4
292	Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit. <i>Frontiers in Pharmacology</i> , 2018, 9, 1436.	1.6	12
293	Impact of genetic polymorphisms on platelet function and response to anti platelet drugs. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 610-620.	0.7	14
294	When will clinical trials finally reflect diversity?. <i>Nature</i> , 2018, 557, 157-159.	13.7	96
295	Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 207-213.	0.7	9
296	Clinical application and importance of one-step human CYP2C19 genotype detection. <i>Journal of International Medical Research</i> , 2018, 46, 4965-4973.	0.4	2
297	Implementing a personalized medicine program in a community health system. <i>Pharmacogenomics</i> , 2018, 19, 1345-1356.	0.6	17

#	ARTICLE	IF	CITATIONS
298	Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations. <i>Pharmacogenomics</i> , 2018, 19, 1203-1216.	0.6	11
299	Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?. <i>Cardiovascular Innovations and Applications</i> , 2018, 3, .	0.1	0
300	Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine. <i>Journal of Personalized Medicine</i> , 2018, 8, 8.	1.1	65
301	Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. <i>Pharmacogenomics</i> , 2018, 19, 771-782.	0.6	13
302	The impact of real-world cardiovascular-related pharmacogenetic testing in an insured population. <i>International Journal of Clinical Practice</i> , 2018, 72, e13088.	0.8	6
303	Clinical Pharmacogenomics. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1561-1571.	2.2	18
304	Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2018, 138, e1-e34.	1.6	316
305	Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention. <i>Cardiovascular Toxicology</i> , 2018, 18, 482-491.	1.1	7
306	Cytochrome P450 in Pharmacogenetics: An Update. <i>Advances in Pharmacology</i> , 2018, 83, 3-32.	1.2	113
307	Clinical outcomes of <i>CYP2C19</i> genotype-guided antiplatelet therapy: existing evidence and future directions. <i>Pharmacogenomics</i> , 2018, 19, 1039-1046.	0.6	23
308	Clopidogrel Pharmacokinetics in Malaysian Population Groups: The Impact of Inter-Ethnic Variability. <i>Pharmaceuticals</i> , 2018, 11, 74.	1.7	4
309	Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine <i>CYP2C19*2</i> genotype?. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1567-1574.	0.8	8
310	Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1115.	1.2	4
311	The <i>ABCBI</i> , <i>CYP2C19</i> , <i>CYP3A5</i> and <i>CYP4F2</i> genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 109-118.	0.3	7
312	Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews. <i>Journal of Medical Genetics</i> , 2018, 55, 617-627.	1.5	24
313	Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A <i>CYP2C19</i> gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 91-98.	0.3	6
314	A synergic effect between <i>CYP2C19*2</i> , <i>CYP2C19*3</i> loss-of-function and <i>CYP2C19*17</i> gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients. <i>BMC Research Notes</i> , 2018, 11, 46.	0.6	10
315	Patient Care Situations Benefiting from Pharmacogenomic Testing. <i>Current Genetic Medicine Reports</i> , 2018, 6, 43-51.	1.9	1

#	ARTICLE	IF	CITATIONS
316	An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 142-152.	0.5	5
317	Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1656-1667.	1.8	26
318	Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 95-106.	0.4	7
319	Cytochrome P450 genotype-guided drug therapies: An update on current states. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 991-1001.	0.9	19
320	Pharmacogenetics. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 147, 59-73.	1.0	16
321	Pharmacogenetics of Clopidogrel Therapy and Neurointerventional Procedures: We Need Precision Data for Precision Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 547-549.	2.3	3
322	The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a033027.	2.9	49
323	Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee. <i>Genetics in Medicine</i> , 2019, 21, 382-390.	1.1	16
324	Impact of <i>SLCO1B1</i> Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 360-373.	2.3	19
325	Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 84-93.	1.2	21
326	Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges. <i>Journal of Personalized Medicine</i> , 2019, 9, 40.	1.1	55
327	A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty. <i>Future Cardiology</i> , 2019, 15, 251-254.	0.5	4
328	The effect of <i>CYP2C19</i> genotype-guided antiplatelet therapy on outcomes of selective percutaneous coronary intervention patients: an observational study. <i>Personalized Medicine</i> , 2019, 16, 301-312.	0.8	4
329	Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 533-546.	1.3	13
330	Diversity in the Era of Precision Medicine - From Bench to Bedside Implementation. <i>Ethnicity and Disease</i> , 2019, 29, 517-524.	1.0	15
331	Both <i>CYP2C19</i> and <i>PON1 Q192R</i> Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome. <i>Cardiovascular Therapeutics</i> , 2019, 1-8.	1.1	24
332	Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 646-650.	0.7	29
333	Actionable Pharmacogenetic Variation in the Slovenian Genomic Database. <i>Frontiers in Pharmacology</i> , 2019, 10, 240.	1.6	10

#	ARTICLE	IF	CITATIONS
334	Structural variation at the CYP2C locus: Characterization of deletion and duplication alleles. Human Mutation, 2019, 40, e37-e51.	1.1	15
335	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	1.1	366
336	Characterizing the pharmacogenome using molecular inversion probes for targeted next-generation sequencing. Pharmacogenomics, 2019, 20, 1005-1020.	0.6	9
337	Pharmacogenomics In Pharmacy Practice: Current Perspectives, Integrated Pharmacy Research & Practice, 2019, Volume 8, 97-104.	0.9	19
338	Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention. Value in Health, 2019, 22, 1231-1239.	0.1	10
339	Pharmacogenomics. Medical Clinics of North America, 2019, 103, 977-990.	1.1	43
340	A Decision-Theoretic Approach to Panel-Based, Preemptive Genotyping. MDM Policy and Practice, 2019, 4, 238146831986433.	0.5	10
341	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting. American Journal of Health-System Pharmacy, 2019, 76, 1395-1402.	0.5	2
342	The Effect of CYP2C19 and Nongenetic Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961987552.	0.7	3
343	Principles of Pharmacogenomics. , 2019, , 1-53.		3
344	Incorporating Pharmacogenomics in Drug Development. , 2019, , 81-101.		1
345	Pharmacogenetics in Cardiovascular Diseases. , 2019, , 133-179.		3
346	Pharmacogenomics Education and Clinical Practice Guidelines. , 2019, , 395-414.		2
347	Non-interventional cardiologists' perspectives on the role of pharmacogenomic testing in cardiovascular medicine. Personalized Medicine, 2019, 16, 123-132.	0.8	11
348	Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention. Clinical Therapeutics, 2019, 41, 1199-1212.e2.	1.1	23
349	Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCI: the POPular Risk Score study. European Journal of Clinical Pharmacology, 2019, 75, 1201-1210.	0.8	16
350	Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis. Biomarkers, 2019, 24, 517-523.	0.9	17
351	Pharmacokinetics and bioequivalence of low-dose clopidogrel in healthy Chinese volunteers under fasted and fed conditions. Drug Metabolism and Pharmacokinetics, 2019, 34, 300-307.	1.1	5

#	ARTICLE	IF	CITATIONS
352	Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. <i>BMJ: British Medical Journal</i> , 2019, 365, l2211.	2.4	86
353	Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e028595.	0.8	3
354	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 680.	3.0	9
355	Anti-Platelet Therapy in Mild Cerebral Infarction Patients on the Basis of CYP2C19 Metabolizer Status. <i>Cell Transplantation</i> , 2019, 28, 1039-1044.	1.2	3
356	Targeted next generation sequencing as a tool for precision medicine. <i>BMC Medical Genomics</i> , 2019, 12, 81.	0.7	54
357	Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users. <i>JAMA Network Open</i> , 2019, 2, e195345.	2.8	95
358	Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI. <i>Thrombosis Research</i> , 2019, 179, 87-94.	0.8	8
359	Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population. <i>Scientific Reports</i> , 2019, 9, 7323.	1.6	14
360	Association of <i>CYP2C19</i> Polymorphisms With Clopidogrel Reactivity and Clinical Outcomes in Chronic Ischemic Stroke. <i>Circulation Journal</i> , 2019, 83, 1385-1393.	0.7	20
361	Acute Respiratory Distress Syndrome Associated With Clopidogrel in a Young Male Patient. <i>Frontiers in Medicine</i> , 2019, 6, 38.	1.2	0
362	Personalized Medicine and the Power of Electronic Health Records. <i>Cell</i> , 2019, 177, 58-69.	13.5	197
363	Comparison between MassARRAY and pyrosequencing for CYP2C19 and ABCB1 gene variants of clopidogrel efficiency genotyping. <i>Molecular Membrane Biology</i> , 2019, 35, 1-8.	2.0	10
364	CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 508-524.	0.7	48
365	High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	4
366	Pharmacogenomic considerations for antiplatelet agents: the era of precision medicine in stroke prevention and neurointerventional practice. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003731.	0.5	4
367	Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine. <i>Genes</i> , 2019, 10, 261.	1.0	13
368	Clinical Utility of <i>CYP2C19</i> Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 647-652.	1.1	65
369	<i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002441.	1.6	10

#	ARTICLE	IF	CITATIONS
370	Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in <i>CYP2C9</i> and <i>CYP2C19</i> . <i>Drug Metabolism and Disposition</i> , 2019, 47, 425-435.	1.7	17
371	Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel. <i>Genetic Testing and Molecular Biomarkers</i> , 2019, 23, 209-214.	0.3	3
372	Research Article RFLP-PCR is more efficient than ARMS-PCR for identifying <i>CYP2C19</i> *2 polymorphism in atherosclerotic patients. <i>Genetics and Molecular Research</i> , 2019, 18, .	0.3	2
373	Pharmacogenetic relevant polymorphisms of <i>CYP2C9</i> , <i>CYP2C19</i> , <i>CYP2D6</i> , and <i>CYP3A5</i> in Bhutanese population. <i>Drug Metabolism and Personalized Therapy</i> , 2019, 34, .	0.3	6
374	Pharmacogenomics and Infectious Diseases in Africa. , 2019, , 95-127.		0
375	Investigating <i>CYP2C19</i> loss-of-function allele statuses and their association with stroke of different etiologies in a Taiwanese population. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 469-472.	0.6	16
376	<p>Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 329-339.	0.4	4
377	Using pharmacogenetics in primary care. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2019, 32, 17-21.	0.1	1
378	Clinical outcomes and predictive model of platelet reactivity to clopidogrel after acute ischemic vascular events. <i>Chinese Medical Journal</i> , 2019, 132, 1053-1062.	0.9	12
379	Targeted ultra-deep sequencing of a South African Bantu-speaking cohort to comprehensively map and characterize common and novel variants in 65 pharmacologically-related genes. <i>Pharmacogenetics and Genomics</i> , 2019, 29, 167-178.	0.7	5
380	An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for <i>CYP2D6</i> , <i>CYP2C19</i> , <i>CYP2C9</i> and <i>VKORC1</i> genes. <i>Journal of Neural Transmission</i> , 2019, 126, 5-18.	1.4	57
381	2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Science Bulletin</i> , 2019, 64, 166-179.	4.3	34
382	Pharmacogenomics research and clinical implementation in Brazil. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 538-549.	1.2	17
383	Role of <i>CYP2C19</i> alleles in the management of recurrent ischemic stroke. <i>Neurology: Clinical Practice</i> , 2019, 9, 140-144.	0.8	3
385	Pharmacogenomics and Precision Medicine. , 2019, , 437-451.		2
386	Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort. <i>Pharmacogenomics</i> , 2019, 20, 75-83.	0.6	3
387	Population-scale genomicsâ€”Enabling precision public health. <i>Advances in Genetics</i> , 2019, 103, 119-161.	0.8	9
388	Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1256-1262.	2.3	90

#	ARTICLE	IF	CITATIONS
389	Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?. Annual Review of Pharmacology and Toxicology, 2019, 59, 577-603.	4.2	19
390	Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. Pharmacogenomics Journal, 2019, 19, 401-410.	0.9	15
391	Integrative Medicine on Optimizing Clopidogrel and Aspirin Therapy. Chinese Journal of Integrative Medicine, 2019, 25, 395-400.	0.7	4
392	Influence of <i>CYP2C19</i> Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure. Clinical Pharmacology and Therapeutics, 2019, 105, 661-671.	2.3	16
393	Pharmacogenetics: The Impact of Genetics on Nutrient-Drug Interactions. , 2020, , 519-524.		0
394	Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. Value in Health, 2020, 23, 61-73.	0.1	30
395	The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. Clinical Pharmacology and Therapeutics, 2020, 107, 171-175.	2.3	207
396	Frequency and clinical outcomes of <i>CYP2C19</i> genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. Genetics in Medicine, 2020, 22, 160-169.	1.1	41
397	Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 203-210.	1.4	69
398	Validation of the Spartan <i>CYP2C19</i> Genotyping Assay Utilizing Blood Samples. Clinical and Translational Science, 2020, 13, 260-264.	1.5	7
399	Potential Clinical Relevance of Differences in Allele Frequencies Found within Very Important Pharmacogenes between Hmong and East Asian Populations. Pharmacotherapy, 2020, 40, 142-152.	1.2	8
400	Defining screening panel of functional variants of <i>CYP1A1</i> , <i>CYP2C9</i> , <i>CYP2C19</i> , <i>CYP2D6</i> , and <i>CYP3A4</i> genes in Serbian population. International Journal of Legal Medicine, 2020, 134, 433-439.	1.2	7
401	Cost-effectiveness of <i>CYP2C19</i> LOF-guided antiplatelet therapy in Chinese patients with acute coronary syndrome. Pharmacogenomics, 2020, 21, 33-42.	0.6	10
402	The Anti-Platelet Anomaly: Aspirin/Dipyridamole-Induced Acute Pancreatitis. American Journal of Medicine, 2020, 133, e220-e222.	0.6	2
403	Antiplatelet Therapy in Flow Diversion. Neurosurgery, 2020, 86, S47-S52.	0.6	40
404	Advances in the Pharmacogenomics of Antiplatelet Therapy. American Journal of Therapeutics, 2020, 27, e477-e484.	0.5	6
405	Evaluating the extent of reusability of <i>CYP2C19</i> genotype data among patients genotyped for antiplatelet therapy selection. Genetics in Medicine, 2020, 22, 1898-1902.	1.1	9
406	Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings. Clinical and Translational Science, 2020, 13, 618-627.	1.5	22

#	ARTICLE	IF	CITATIONS
407	Pharmacogenomics in kidney transplant recipients and potential for integration into practice. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1457-1465.	0.7	3
409	Tailored antiplatelet agent medication in clopidogrel hyporesponsive patients before stent-assisted coiling: single-center experience. <i>Neuroradiology</i> , 2020, 62, 1709-1715.	1.1	7
410	Pharmacogenomics for Primary Care: An Overview. <i>Genes</i> , 2020, 11, 1337.	1.0	30
411	Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study. <i>BMC Medicine</i> , 2020, 18, 367.	2.3	13
412	<p>Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 239-252.	0.4	14
414	Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic. <i>Journal of Clinical Medicine</i> , 2020, 9, 2274.	1.0	29
415	Scientific considerations for global drug development. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	8
416	<i>CYP2C19</i> genotype-guided antiplatelet therapy: promises and pitfalls. <i>Pharmacogenomics</i> , 2020, 21, 889-897.	0.6	13
417	CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019. <i>Medicine (United States)</i> , 2020, 99, e20582.	0.4	6
418	Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study. <i>BMJ Open</i> , 2020, 10, e038031.	0.8	2
419	Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial. <i>BMJ Open</i> , 2020, 10, e038936.	0.8	10
420	Measuring preferences for <i>CYP2C19</i> genotyping in patients with acute coronary syndrome â€“ a discrete choice experiment. <i>Future Cardiology</i> , 2020, 16, 663-674.	0.5	2
421	Exploring pharmacogenetic difference using adverse event database: an example of clopidogrel and cardiovascular events. <i>Pharmacogenomics</i> , 2020, 21, 1157-1168.	0.6	2
422	Distribution of <i>CYP2C19</i>, <i>ABCB1</i> and <i>PON1</i> polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease. <i>International Journal of Immunogenetics</i> , 2020, 47, 539-545.	0.8	7
423	Moving Genomics to Routine Care. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, 406-416.	1.6	11
424	Precision Medicine: Steps along the Road to Combat Human Cancer. <i>Cells</i> , 2020, 9, 2056.	1.8	29
425	Optimising Seniorsâ€™ Metabolism of Medications and Avoiding Adverse Drug Events Using Data on How Metabolism by Their P450 Enzymes Varies with Ancestry and Drugâ€™Drugâ€™Gene Interactions. <i>Journal of Personalized Medicine</i> , 2020, 10, 84.	1.1	4
426	Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization. <i>Pharmaceutics</i> , 2020, 12, 1240.	2.0	20

#	ARTICLE	IF	CITATIONS
427	Effects of individualized antiplatelet therapy, based on CYP2C19 genotyping, on platelet function in patients underwent percutaneous coronary intervention. <i>Perfusion (United Kingdom)</i> , 2020, , 026765912097858.	0.5	5
428	Establishment of a Pharmacogenetics Service Focused on Optimizing Existing Pharmacogenetic Testing at a Large Academic Health Center. <i>Journal of Personalized Medicine</i> , 2020, 10, 154.	1.1	12
429	Prevalence and types of inconsistencies in clinical pharmacogenetic recommendations among major U.S. sources. <i>Npj Genomic Medicine</i> , 2020, 5, 48.	1.7	19
430	Variant discovery using next-generation sequencing and its future role in pharmacogenetics. <i>Pharmacogenomics</i> , 2020, 21, 471-486.	0.6	9
431	High on-clopidogrel platelet reactivity in ischaemic stroke or transient ischaemic attack: Systematic review and meta-analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104877.	0.7	24
432	Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients. <i>Pharmacogenomics</i> , 2020, 21, 431-441.	0.6	7
433	Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators. <i>Drug Metabolism and Disposition</i> , 2020, 48, 230-244.	1.7	62
434	How to Transition from Singleâ€Gene Pharmacogenetic Testing to Preemptive Panelâ€Based Testing: A Tutorial. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 557-565.	2.3	24
435	Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1/*17 genotype suggesting a rapid metabolizer status. <i>Pharmacogenomics Journal</i> , 2020, 20, 840-844.	0.9	2
436	The landscape of pharmacogenetic testing in a US managed care population. <i>Genetics in Medicine</i> , 2020, 22, 1247-1253.	1.1	27
437	The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. <i>Platelets</i> , 2020, 31, 971-980.	1.1	10
438	Age-dependent association of CYP2C19 polymorphisms with clinical outcome of clopidogrel therapy in minor stroke patients with large-artery atherosclerosis. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1263-1271.	0.8	0
439	CYP2C19 Allele Frequencies in Over 2.2 Million Directâ€toâ€Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health System. <i>Clinical and Translational Science</i> , 2020, 13, 1298-1306.	1.5	34
440	Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. <i>Advances in Therapy</i> , 2020, 37, 3537-3550.	1.3	16
441	The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention. <i>Medicine (United States)</i> , 2020, 99, e19143.	0.4	6
442	Genotype and Phenotype Concordance for Pharmacogenetic Tests Through Proficiency Survey Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1057-1066.	1.2	5
443	<p>Impacts of CYP2C19 Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 669-676.	2.0	4
444	Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 179-188.	1.3	8

#	ARTICLE	IF	CITATIONS
445	Antithrombotic Strategy for Patients with Acute Coronary Syndrome: A Perspective from East Asia. <i>Journal of Clinical Medicine</i> , 2020, 9, 1963.	1.0	18
446	Individualized Medication Management in Ontario Long-Term Care Clinical Impact on Management of Depression, Pain, and Dementia. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 823-829.e5.	1.2	14
447	PARC report: a perspective on the state of clinical pharmacogenomics testing. <i>Pharmacogenomics</i> , 2020, 21, 809-820.	0.6	8
448	Association between CYP2C19 gene polymorphisms and lipid metabolism in Chinese patients with ischemic stroke. <i>Journal of International Medical Research</i> , 2020, 48, 030006052093465.	0.4	6
449	Perspective on <i>CYP2C19</i> genotyping test among patients with acute coronary syndrome – a qualitative study. <i>Future Cardiology</i> , 2020, 16, 655-662.	0.5	1
450	<p>CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 29-37.	0.4	10
451	Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications. <i>Clinical and Translational Science</i> , 2020, 13, 861-870.	1.5	42
452	Precision medication: An illustrative case series guiding the clinical application of multi-â€drug interactions and pharmacogenomics. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 305-312.	0.2	8
453	Applying whole-genome sequencing in relation to phenotype and outcomes in siblings with cystic fibrosis. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004531.	0.5	7
454	Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience. <i>Pharmacogenomics</i> , 2020, 21, 375-386.	0.6	37
455	Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. <i>Pharmacogenomics Journal</i> , 2020, 20, 724-735.	0.9	25
456	Prospective <i>CYP2C19</i> Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002640.	1.6	39
457	Genotype-guided treatment of oral P2Y12 inhibitors: where do we stand?. <i>Pharmacogenomics</i> , 2020, 21, 83-86.	0.6	5
458	The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 604.	1.8	35
459	Antiaggregation effect of clopidogrel in coronary heart disease patients using omeprazole. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2020, 30, .	0.7	1
460	Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data. <i>Pharmacogenomics</i> , 2020, 21, 141-156.	0.6	39
461	Pharmacogenomics in pregnancy. <i>Seminars in Perinatology</i> , 2020, 44, 151222.	1.1	12
462	Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 201-211.	1.0	19

#	ARTICLE	IF	CITATIONS
464	The ChinaMAP analytics of deep whole genome sequences in 10,588 individuals. <i>Cell Research</i> , 2020, 30, 717-731.	5.7	165
465	Pharmacogeneticâ€Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 338-349.	2.3	2
466	Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of ticagrelor, a novel thienopyridine P2Y₁₂ inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1860-1874.	1.1	12
467	Metabolism of a New Antiaggregant, Indolinone Derivative. <i>Bulletin of Experimental Biology and Medicine</i> , 2020, 168, 739-742.	0.3	1
468	Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and metaâ€analysis. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1489-1498.	1.1	16
469	Clinically relevant pharmacogenetic markers in Tatars and Balkars. <i>Molecular Biology Reports</i> , 2020, 47, 3377-3387.	1.0	3
471	World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI. <i>Global Heart</i> , 2020, 9, 457.	0.9	34
472	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 549-559.	1.3	6
473	PharmVar GeneFocus: <i>CYP2C19</i>. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 352-366.	2.3	72
474	Patient perceptions of pharmacogenomic testing in the community pharmacy setting. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 744-749.	1.5	19
475	Risk of major adverse cardiovascular events of <i>CYP2C19</i> loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. <i>Platelets</i> , 2021, 32, 591-600.	1.1	22
476	Global distribution of CYP2C19 risk phenotypes affecting safety and effectiveness of medications. <i>Pharmacogenomics Journal</i> , 2021, 21, 190-199.	0.9	13
477	A Tutorial for Pharmacogenomics Implementation Through Endâ€toâ€End Clinical Decision Support Based on Ten Years of Experience from PREDICT. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 101-115.	2.3	34
478	Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 643-650.	0.8	11
479	Multiplex allele-specific detection of clinically important CYP2C19 variants associated with clopidogrel metabolism in a Bangladeshi population sample. <i>Meta Gene</i> , 2021, 27, 100830.	0.3	1
480	CYP2C19 Genotype-Guided Antiplatelet Therapy Among Asian Patients with Ischaemic Stroke. <i>Clinical Drug Investigation</i> , 2021, 41, 115-116.	1.1	2
481	CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105464.	0.7	9
482	Polypharmacy, potentially inappropriate medication and pharmacogenomics drug exposure in the Rhineland Study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2732-2756.	1.1	8

#	ARTICLE	IF	CITATIONS
483	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2021, 121, 422-432.	1.8	149
484	Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111087.	2.5	12
485	Pharmacogenomics: Prescribing based on genetic variation. <i>InnovAiT</i> , 2021, 14, 116-123.	0.0	1
486	Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States. <i>Clinical and Translational Science</i> , 2021, 14, 153-162.	1.5	9
487	The need of a multicomponent guiding approach to personalize clopidogrel treatment. <i>Pharmacogenomics Journal</i> , 2021, 21, 116-127.	0.9	8
488	Clopidogrel Dosing: Current Successes and Emerging Factors for Further Consideration. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1203-1211.	2.3	5
489	Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 705-715.	2.3	25
490	Group-based pharmacogenetic prediction: is it feasible and do current NHS England ethnic classifications provide appropriate data?. <i>Pharmacogenomics Journal</i> , 2021, 21, 47-59.	0.9	3
491	Precision Medicine and Informatics. , 2021, , 941-966.		0
492	Prevalence of CYP2C19 and ITGB3 polymorphisms among Bangladeshi patients who underwent percutaneous coronary intervention. <i>SAGE Open Medicine</i> , 2021, 9, 205031212110422.	0.7	3
493	Precision Medicine in Kidney Transplantation: Just Hype or a Realistic Hope?. <i>Transplantation Direct</i> , 2021, 7, e650.	0.8	8
495	Combination of Genome-Wide Polymorphisms and Copy Number Variations of Pharmacogenes in Koreans. <i>Journal of Personalized Medicine</i> , 2021, 11, 33.	1.1	3
496	Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China. <i>Frontiers in Pharmacology</i> , 2020, 11, 582929.	1.6	13
497	Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPgX Guidelines. <i>Frontiers in Pharmacology</i> , 2020, 11, 595219.	1.6	103
498	Pharmacogenetics and personalized medicine. , 2021, , 193-219.		0
499	Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing. <i>Clinical and Translational Science</i> , 2021, 14, 784-790.	1.5	1
500	Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 179-188.	2.3	35
501	The Interface of Therapeutics and Genomics in Cardiovascular Medicine. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 663-676.	1.3	8

#	ARTICLE	IF	CITATIONS
502	CYP2C19 Loss-of-Function Associated with First-Time Ischemic Stroke in Non-surgical Asymptomatic Carotid Artery Stenosis During Clopidogrel Therapy. <i>Translational Stroke Research</i> , 2022, 13, 46-55.	2.3	3
503	The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 85-99.	1.4	23
504	Correlation study of CYP2C19 gene polymorphism and clopidogrel resistance in Han Chinese patients with cerebral infarction in Guizhou region. <i>Medicine (United States)</i> , 2021, 100, e24481.	0.4	1
505	Anatomical distribution and expression of CYP in humans: Neuropharmacological implications. <i>Drug Development Research</i> , 2021, 82, 628-667.	1.4	11
506	Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy. <i>Metabolites</i> , 2021, 11, 96.	1.3	7
507	P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor. <i>Heart</i> , 2021, 107, 1077-1083.	1.2	5
508	Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 1360-1369.	1.0	12
509	Access to precision medicine in Thailand: a comparative study. <i>Journal of Health Research</i> , 2022, 36, 275-288.	0.4	1
510	The Case for Expanding the FDA Box Warning on Clopidogrel to CYP2C19 Intermediate Metabolizers. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 860-862.	2.3	2
512	Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism. <i>Medicine (United States)</i> , 2021, 100, e24545.	0.4	8
513	SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. <i>Journal of Personalized Medicine</i> , 2021, 11, 204.	1.1	19
514	Impact of genetic variants on clinical outcome after percutaneous coronary intervention in elderly patients. <i>Aging</i> , 2021, 13, 6506-6524.	1.4	1
515	Association between CYP2C19 polymorphisms and clinical outcomes in patients undergoing stent procedure for cerebral artery stenosis. <i>Scientific Reports</i> , 2021, 11, 5974.	1.6	4
516	Ischemic stroke and myocardial ischemia in clopidogrel users and the association with CYP2C19 loss-of-function homozygosity: a real-world study. <i>Pharmacogenomics Journal</i> , 2021, 21, 402-408.	0.9	5
517	The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD). <i>Molecules</i> , 2021, 26, 1987.	1.7	30
518	CYP2C19 Polymorphisms in Indonesia: Comparison among Ethnicities and the Association with Clinical Outcomes. <i>Biology</i> , 2021, 10, 300.	1.3	0
519	Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism. <i>Frontiers in Pharmacology</i> , 2021, 12, 660639.	1.6	1
520	Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 739-750.	1.1	90

#	ARTICLE	IF	CITATIONS
521	Genetic variants related to successful migraine prophylaxis with verapamil. <i>Molecular Genetics & Genomic Medicine</i> , 2021, 9, e1680.	0.6	8
522	PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS. <i>Farmatsiya I Farmakologiya</i> , 2021, 8, 392-404.	0.2	2
523	A Pharmacogenetic Study of CYP2C19 in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy. <i>Journal of Personalized Medicine</i> , 2021, 11, 400.	1.1	4
524	Therapeutic Dilemma in personalized medicine. <i>Current Reviews in Clinical and Experimental Pharmacology</i> , 2021, 16, .	0.4	0
525	Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital. <i>Journal of Personalized Medicine</i> , 2021, 11, 394.	1.1	14
526	CYP2C19 genotype-directed P2Y12 inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention. <i>Indian Heart Journal</i> , 2021, 73, 281-288.	0.2	1
527	Pharmacogenetics to guide cardiovascular drug therapy. <i>Nature Reviews Cardiology</i> , 2021, 18, 649-665.	6.1	49
528	Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting. <i>JAMA Network Open</i> , 2021, 4, e2110446.	2.8	22
529	Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 963-978.	1.3	27
530	Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. <i>Circulation Research</i> , 2021, 128, 1973-1987.	2.0	10
531	Is monitoring of antiplatelet therapy by light transmission aggregometry dependent on instrument and reagent used?. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 786-794.	0.7	3
532	Clopidogrel underactivity is a common in patients with acute symptomatic severe carotid stenosis. <i>Journal of the Neurological Sciences</i> , 2021, 425, 117450.	0.3	2
533	Safety considerations with the use of platelet inhibitors for elderly patients with non-ST- elevation acute coronary syndrome. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-8.	1.0	2
534	Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population. <i>Scientific Reports</i> , 2021, 11, 12343.	1.6	16
535	Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review. <i>Frontiers in Neurology</i> , 2021, 12, 667234.	1.1	8
536	Mechanistic insights into the CYP2C19 genetic variants prevalent in the Indian population. <i>Gene</i> , 2021, 784, 145592.	1.0	2
537	Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, 161-167.	0.8	6
538	New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin. <i>Pharmacogenomics Journal</i> , 2021, 21, 664-672.	0.9	5

#	ARTICLE	IF	CITATIONS
539	Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 676954.	1.1	4
540	Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform. <i>Journal of Applied Laboratory Medicine</i> , 2021, 6, 1505-1516.	0.6	6
541	Personalized medicine in cardiovascular disease: review of literature. <i>Journal of Diabetes and Metabolic Disorders</i> , 2021, 20, 1793-1805.	0.8	8
542	Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-Conscious Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 909-925.	2.3	19
543	Effects of aging on clinical outcomes in patients receiving genotype-guided P2Y12 inhibitor selection after percutaneous coronary intervention. <i>Pharmacotherapy</i> , 2021, , .	1.2	3
544	Efficacy and Safety of Aspirin Combined with Low-Dose P2Y12 Receptor Antagonists in East Asian Patients Undergoing PCI. <i>International Heart Journal</i> , 2021, 62, 742-751.	0.5	0
545	Genome-Wide Approach to Measure Variant-Based Heritability of Drug Outcome Phenotypes. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 714-722.	2.3	7
546	Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach. <i>Clinical and Translational Science</i> , 2021, 14, 2254-2266.	1.5	15
547	Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 735-755.	1.6	3
548	Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis. <i>European Journal of Internal Medicine</i> , 2021, 90, 49-65.	1.0	10
549	Precision Medicine and Adverse Drug Reactions Related to Cardiovascular Drugs. <i>Diseases (Basel)</i> , 2021, 10, 3772.	1.0	3
550	Clopidogrel versus Ticagrelor in CYP2C19 Loss-of-Function Allele Noncarriers: A Real-World Study in China. <i>Thrombosis and Haemostasis</i> , 2021, , .	1.8	3
551	Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial. <i>Clinical and Translational Science</i> , 2021, 14, 2532-2543.	1.5	9
552	PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics. <i>Journal of Clinical Medicine</i> , 2021, 10, 3772.	1.0	12
553	Applications for pharmacogenomics in pharmacy practice: A scoping review. <i>Research in Social and Administrative Pharmacy</i> , 2022, 18, 3094-3118.	1.5	20
554	Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uyghur population with acute coronary syndrome: a retrospective study. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 391.	0.7	6
555	The Propagation of Racial Disparities in Cardiovascular Genomics Research. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003178.	1.6	14
556	Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests. <i>Pharmacogenomics Journal</i> , 2021, , .	0.9	0

#	ARTICLE	IF	CITATIONS
557	Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics. <i>Pharmaceutics</i> , 2021, 13, 1573.	2.0	4
558	Rationale and design of the BA-SCAD (Beta-blockers and Antiplatelet agents in patients with) Tj ETQq1 1 0.784314 rgBT /Overlock 10 (English Ed), 2022, 75, 515-522.	0.4	11
559	The Gene-Drug Duality: Exploring the Pharmacogenomics of Indigenous Populations. <i>Frontiers in Genetics</i> , 2021, 12, 687116.	1.1	3
560	Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 195-206.	1.0	13
561	Pharmacogenetics in Pharmaceutical Careâ€”Piloting an Application-Oriented Blended Learning Concept. <i>Pharmacy (Basel, Switzerland)</i> , 2021, 9, 152.	0.6	4
562	Differential Impact of Cytochrome 2C19 Allelic Variants on Three Different Platelet Function Tests in Clopidogrel-Treated Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 3992.	1.0	1
563	High On-Treatment Platelet Reactivity as Predictor of Long-term Clinical Outcomes in Stroke Patients with Antiplatelet Agents. <i>Translational Stroke Research</i> , 2022, 13, 391-398.	2.3	6
564	The impact of a 1â€hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. <i>International Journal of Cancer</i> , 2021, 148, 2799-2806.	2.3	8
565	Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore. <i>Pharmacogenomics Journal</i> , 2021, 21, 243-250.	0.9	8
566	<i>ABCB1</i> polymorphism in clopidogrel-treated Montenegrin patients. <i>Open Life Sciences</i> , 2021, 16, 142-149.	0.6	1
567	Sources of Interindividual Variability. <i>Methods in Molecular Biology</i> , 2021, 2342, 481-550.	0.4	7
568	Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. <i>JAMA Network Open</i> , 2020, 3, e2029411.	2.8	34
569	Sources of Interindividual Variability. <i>Methods in Molecular Biology</i> , 2014, 1113, 363-415.	0.4	34
570	Comparison Between Clopidogrel and Prasugrel Associated With <i>CYP2C19</i> Genotypes in Patients Receiving Percutaneous Coronary Intervention in a Japanese Population. <i>Circulation Journal</i> , 2020, 84, 1575-1581.	0.7	12
571	Analysis of the CYP2C19 Genetic Polymorphism in Han and Uyghur patients with Cardiovascular and Cerebrovascular Diseases in the Kashi Area of Xinjiang. <i>Medical Science Monitor</i> , 2014, 20, 2213-2218.	0.5	12
572	Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data. <i>PLoS ONE</i> , 2016, 11, e0164169.	1.1	8
573	Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation. <i>PLoS ONE</i> , 2017, 12, e0169233.	1.1	66
574	Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. <i>PLoS ONE</i> , 2017, 12, e0175508.	1.1	268

#	ARTICLE	IF	CITATIONS
575	Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke. PLoS ONE, 2020, 15, e0236260.	1.1	3
576	CYP2C19*2 Allele Carrier Status and Coronary In-stent Restenosis: Is There an Association?. Journal of Exploratory Research in Pharmacology, 2018, 3, 55-60.	0.2	4
577	Using Pharmacogenetic Testing or Platelet Reactivity Testing to Tailor Antiplatelet Therapy: Are Asians different from Caucasians?. European Cardiology Review, 2018, 13, 112.	0.7	11
579	Protease activated receptor 4: a backup receptor or a dark horse as a target in antiplatelet therapy?. Annals of Translational Medicine, 2018, 6, 56-56.	0.7	3
580	Pharmacogenetics of Obesity Drug Therapy. Current Molecular Medicine, 2014, 14, 891-908.	0.6	11
581	Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways. Current Vascular Pharmacology, 2018, 17, 35-40.	0.8	8
582	Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting. Current Clinical Pharmacology, 2017, 12, 11-17.	0.2	16
583	Assessment of primary care practitioners' attitudes and interest in pharmacogenomic testing. Pharmacogenomics, 2020, 21, 1085-1094.	0.6	24
584	An Interdisciplinary Experience focused on Pharmacogenetics: Engaging pharmacy and physician assistant students in conversations about antiplatelet therapy with respect to CYP2C19 genotype. Innovations in Pharmacy, 2016, 7, .	0.2	11
586	Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues in Clinical Neuroscience, 2016, 18, 323-337.	1.8	38
587	Use of pharmacogenomics in elderly patients treated for cardiovascular diseases. Croatian Medical Journal, 2020, 61, 147-158.	0.2	4
588	Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines Part 2. Laboratory Medicine Online, 2016, 6, 193.	0.0	4
589	Pharmacogenomics: An evolving clinical tool for precision medicine. Cleveland Clinic Journal of Medicine, 2020, 87, 91-99.	0.6	34
590	A conceptual model for translating omic data into clinical action. Journal of Pathology Informatics, 2015, 6, 46.	0.8	17
591	Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Pharmacy Practice, 2014, 12, 0-0.	0.8	21
592	Pharmacogenomics and Rheumatological Practice. Journal of Clinical Rheumatology and Immunology, 0, , 1-12.	0.4	0
593	Impact of Updating Pharmacogenetic Results: Lessons Learned from the PREDICT Program. Journal of Personalized Medicine, 2021, 11, 1051.	1.1	4
594	Nine-gene pharmacogenomics profile service: The Mayo Clinic experience. Pharmacogenomics Journal, 2021, , .	0.9	13

#	ARTICLE	IF	CITATIONS
595	Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health. <i>Human Genetics</i> , 2022, 141, 1113-1136.	1.8	17
596	Impact of Automated Best Practice Advisories on Provider Response to <i>CYP2C19</i> Genotyping Results for Patients on Clopidogrel. <i>Journal of Pharmacy Practice</i> , 2023, 36, 487-493.	0.5	2
598	Pharmacogenetic Testing for Anticoagulant and Antiplatelet Therapies. , 2015, , 173-181.		0
601	Platelets and Polymorphisms. <i>Cardiac and Vascular Biology</i> , 2017, , 275-292.	0.2	0
602	Pharmacogenomics and Cardiovascular Disease. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2017, , 161-174.	0.1	0
603	Stable Ischemic Heart Disease. , 2017, , .		0
606	Charting a Course for Genomic Medicine from Base Pair to Bedside. , 2018, , 215-225.		0
607	Clinical Pharmacogenomics and Personalized Medicine: New Strategies to Maximize Drug Efficacy and Avoid Adverse Drug Reaction. , 2018, , 239-261.		0
610	Pharmacogenomics and Cardiovascular Disease. , 2019, , 184-197.		0
611	Personalized antiplatelet and anticoagulation therapy: Pharmacogenomics. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2019, 30, 850-855.	0.1	0
614	Ethnic Differences in Oral Antithrombotic Therapy. <i>Korean Circulation Journal</i> , 2020, 50, 645.	0.7	13
615	Clinical Outcomes After Percutaneous Coronary Intervention Over Time on the Basis of <i>CYP2C19</i> Polymorphisms. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, 183-191.	0.8	3
616	Influence of <i>GAS5</i> /MicroRNA-223/P2Y12 Axis on Clopidogrel Response in Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2021, 10, e021129.	1.6	9
617	Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. <i>Current Pharmaceutical Design</i> , 2020, 26, 5988-5997.	0.9	5
618	Antiplatelet effect of ticagrelor with aspirin in acute minor stroke and transient ischemic attack stratified by <i>CYP2C19</i> metabolizer status: subgroup analysis of the PRINCE trial. <i>Aging</i> , 2021, 13, 3994-4006.	1.4	2
619	Effect of genotype-guided strategy in East Asian vs. Caucasian patients after percutaneous coronary intervention: insight from the TAILOR-PCI trial. <i>Journal of Thoracic Disease</i> , 2020, 12, 7501-7503.	0.6	1
620	Biochip-based approach for comprehensive pharmacogenetic testing. <i>Drug Metabolism and Personalized Therapy</i> , 2021, 36, 33-40.	0.3	3
621	Cartographic atlas of frequency variation for 45 pharmacogenetic markers in populations of Russia and its neighbor states. <i>Bulletin of Russian State Medical University</i> , 2020, , .	0.3	7

#	ARTICLE	IF	CITATIONS
622	Clinical pharmacogenetics. , 2022, , 189-212.		0
623	Chapter 7: Cardiology: Clopidogrel/ <i>CYP2C19</i> Case. , 2020, , .		0
624	Chapter 27: Pharmacogenomics Testing. , 2020, , .		0
625	Pharmacogenomics of Antithrombotic Drugs. , 2020, , 137-153.		0
626	Precision medicine in neurology. , 2020, , 27-39.		1
627	Chapter 1: Foundations of Pharmacogenomics. , 2020, , .		0
628	Allele and Genotype Frequencies of CYP2C19 in Patients with Drug-Eluting Stents Following Percutaneous Coronary Intervention in Southwest of Iran. Jundishapur Journal of Chronic Disease Care, 2020, 9, .	0.1	0
629	Genetic Disorders. , 2020, , 1-15.		0
630	Chapter 2: Pharmacogenomics: Drug Exposure and Response. , 2020, , .		0
631	Dual antiplatelet Tx for stroke prevention: Worth the risk?. , 2020, 69, .		0
634	Drug-gene interactions: inherent variability in drug maintenance dose requirements. P and T, 2014, 39, 630-7.	1.0	11
636	Pharmacogenetics: Using Genetic Information to Guide Drug Therapy. American Family Physician, 2015, 92, 588-94.	0.1	17
637	Using Workflow Modeling to Identify Areas to Improve Genetic Test Processes in the University of Maryland Translational Pharmacogenomics Project. AMIA ... Annual Symposium proceedings, 2015, 2015, 466-74.	0.2	4
638	A Knowledge-based System for Intelligent Support in Pharmacogenomics Evidence Assessment: Ontology-driven Evidence Representation and Retrieval. AMIA Summits on Translational Science Proceedings, 2017, 2017, 175-184.	0.4	0
639	The Daniel K. Inouye College of Pharmacy Scripts: Precision Medicine Through the Use of Pharmacogenomics: Current Status and Barriers to Implementation. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2017, 76, 265-269.	0.4	0
640	Pharmacogenomics: What the Doctor Ordered?. Missouri Medicine, 2019, 116, 217-225.	0.3	1
641	Genetic Polymorphism of CYP2C19 in Pakistani Population. Iranian Journal of Pharmaceutical Research, 2019, 18, 1097-1102.	0.3	3
642	Translating Pharmacogenomic Research to Therapeutic Potentials (Bench to Bedside). , 2021, , .		0

#	ARTICLE	IF	CITATIONS
643	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. <i>European Journal of Human Genetics</i> , 2022, 30, 1114-1120.	1.4	37
644	Race and Drug Toxicity: A Study of Three Cardiovascular Drugs with Strong Pharmacogenetic Recommendations. <i>Journal of Personalized Medicine</i> , 2021, 11, 1226.	1.1	3
645	Pharmacogenomic analysis of a genetically distinct Indigenous population. <i>Pharmacogenomics Journal</i> , 2021, , .	0.9	4
647	MicroRNAs as Novel Biomarkers for P2Y12 Inhibitors Resistance Prediction. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1575-1582.	0.4	3
648	Computational Methods and Approaches in Pharmacogenomic Research. , 2022, , 53-83.		1
649	Arzneimitteltherapiesicherheit: Interaktionen der Thrombozytenaggregationshemmer. , 0, , .		0
650	Frequencies of Clinically Important CYP2C19 and CYP2D6 Alleles across East Asian populations. , 2021, , .		1
651	Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Acute Coronary Syndrome: A Comprehensive Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 818215.	1.1	9
652	Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes. <i>Pharmacogenomics Journal</i> , 2022, , .	0.9	0
653	Antiplatelet Therapy for Atherothrombotic Disease in 2022"From Population to Patient-Centered Approaches. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 805525.	1.1	12
654	Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population. <i>PLoS ONE</i> , 2022, 17, e0263137.	1.1	10
655	Pharmacogenomics in bipolar disorder: towards precision psychiatry and personalized treatment. , 2022, , 483-496.		0
656	Automated Pharmacogenomic Reports for Clinical Genome Sequencing. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 205-218.	1.2	5
657	How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	1.1	3
658	Pharmacogenetic differentiation across Latin America. <i>Pharmacogenomics</i> , 2022, 23, 225-233.	0.6	5
659	Antiplatelet Use in Ischemic Stroke. <i>Annals of Pharmacotherapy</i> , 2022, 56, 1159-1173.	0.9	18
660	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Cardiovascular Revascularization Medicine</i> , 2022, 41, 115-121.	0.3	4
661	Attitudes toward pharmacogenetics in patients undergoing CYP2C19 testing following percutaneous coronary intervention. <i>Personalized Medicine</i> , 2022, 19, 93-101.	0.8	2

#	ARTICLE	IF	CITATIONS
662	Identification of Potential Biological Factors Affecting the Treatment of Ticagrelor After Percutaneous Coronary Intervention in the Chinese Population. <i>Pharmacogenomics and Personalized Medicine</i> , 2022, Volume 15, 29-43.	0.4	2
663	Genetic Disorders. , 2022, , 207-221.		0
664	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2C19</i> Genotype and Clopidogrel Therapy: 2022 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 959-967.	2.3	166
665	Clopidogrel Use and <i>CYP2C19</i> Genotypes in Patients Undergoing Vascular Intervention Procedure: A Hospital-Based Study. <i>Pharmacogenomics and Personalized Medicine</i> , 2022, Volume 15, 81-89.	0.4	2
666	Effects of the <i>CYP2C19</i> LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. <i>Pharmacogenomics</i> , 2022, 23, 207-220.	0.6	14
667	<i>CYP2C8</i> , <i>CYP2C9</i> , and <i>CYP2C19</i> Characterization Using Next-Generation Sequencing and Haplotype Analysis. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 337-350.	1.2	23
668	<i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. <i>Journal of the American Heart Association</i> , 2022, 11, e024159.	1.6	24
669	The pharmacist's responsibility to ensure appropriate use of direct-to-consumer genetic testing. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 652-658.	0.5	4
670	P2Y12 Reaction Units and Clinical Outcomes in Acute Large Artery Atherosclerotic Stroke: A Multicenter Prospective Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 39-55.	0.9	2
671	Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations. <i>JACC Asia</i> , 2022, 2, 1-18.	0.5	15
672	Comparative evaluation of standard maintenance-dose clopidogrel versus low-dose prasugrel in patients with stable coronary artery disease after percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2022, , .	0.8	2
673	Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. <i>Frontiers in Pharmacology</i> , 2022, 13, 835136.	1.6	17
674	Implementation of <i>CYP2D6</i> copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder. <i>Pharmacogenomics Journal</i> , 2022, 22, 166-172.	0.9	6
675	<i>CYP2C19</i> plays a major role in the hepatic <i>N</i> -oxidation of cotinine. <i>Drug Metabolism and Disposition</i> , 2022, , DMD-AR-2021-000624.	1.7	4
676	A population study of clinically actionable genetic variation affecting drug response from the Middle East. <i>Npj Genomic Medicine</i> , 2022, 7, 10.	1.7	20
677	Increased frequency of <i>CYP2C19</i> loss-of-function alleles in clopidogrel-treated patients with recurrent cerebral ischemia. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3335-3340.	1.1	3
678	Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel. <i>Stroke and Vascular Neurology</i> , 2022, 7, 310-318.	1.5	2
679	Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 850028.	1.1	4

#	ARTICLE	IF	CITATIONS
680	A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00946.	1.1	4
681	Influence of CYP2D6, CYP3A4 and CYP2C19 Genotypes on Recurrence of <i>Plasmodium vivax</i> . <i>Frontiers in Tropical Diseases</i> , 2022, 3, .	0.5	1
682	The U.S. National Library of Medicine's impact on precision and genomic medicine. <i>Information Services and Use</i> , 2022, , 1-10.	0.1	0
683	Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation. <i>Pharmacogenetics and Genomics</i> , 2022, 32, 183-191.	0.7	5
684	Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis. <i>Pharmacogenomics Journal</i> , 2022, 22, 188-197.	0.9	4
685	High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 1112-1121.	0.7	5
686	CYP2C19*2 genetic polymorphism and incidence of in-stent restenosis in patients on clopidogrel: a matched case-control study. <i>Drug Metabolism and Personalized Therapy</i> , 2022, 37, 155-161.	0.3	2
687	Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy. <i>Pharmacogenetics and Genomics</i> , 2021, Publish Ahead of Print, .	0.7	0
688	The Landscape of Clinical Implementation of Pharmacogenetic Testing in Central China: A Single-Center Study. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1619-1628.	0.4	2
689	Genetic Risk Factors for Adverse Drug Reactions. <i>Safety and Risk of Pharmacotherapy</i> , 2022, 10, 48-64.	0.1	3
694	Point of care CYP2C19 genotyping after percutaneous coronary intervention. <i>Pharmacogenomics Journal</i> , 2022, , .	0.9	0
695	High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial. <i>Acta Cardiologica</i> , 2016, 71, 309-16.	0.3	14
697	Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review. <i>AIMS Molecular Science</i> , 2022, 9, 66-78.	0.3	1
698	The Efficacy of a Didactic and Case-Based Pharmacogenomics Education Program on Improving the Knowledge and Confidence of Alberta Pharmacists. <i>Pharmacogenomics and Personalized Medicine</i> , 2022, Volume 15, 409-427.	0.4	2
699	Pharmacogenetics of Donepezil and Memantine in Healthy Subjects. <i>Journal of Personalized Medicine</i> , 2022, 12, 788.	1.1	3
700	The Cytochrome P450 2C19 Polymorphism is Associated with Major Adverse Cardiovascular Events Risk in Kazak Patients Undergoing Percutaneous Coronary Intervention and Receiving Clopidogrel. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, .	0.6	0
701	Knowledge, attitude and perception of community pharmacists towards pharmacogenomics services in northern Nigeria: a cross-sectional study. <i>Journal of Pharmaceutical Policy and Practice</i> , 2022, 15, .	1.1	4
702	How Can We Prevent Both Bleeding and Ischemic Events After Percutaneous Coronary Intervention in High-Bleeding Risk Patients?. <i>Circulation Journal</i> , 2022, , .	0.7	0

#	ARTICLE	IF	CITATIONS
703	Cost-effectiveness of <i>CYP2C19</i> -guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2023, 9, 249-257.	1.8	3
704	Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with <i>CYP2C19</i> polymorphisms: a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1217-1225.	0.8	5
705	Advancing equity in the promise of pharmacogenomics. , 2022, , 85-106.		1
706	Clinical considerations for precision medicine clinical decision support. , 2022, , 175-200.		1
707	Pharmacogenomic Clinical Decision Support: A Scoping Review. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 803-815.	2.3	8
708	Semi-mechanistic Population Pharmacokinetics Analysis Reveals Distinct <i>CYP2C19</i> Dependency in the Bioactivation of Vicagrel and Clopidogrel to Active Metabolite M15-2. <i>European Journal of Pharmaceutical Sciences</i> , 2022, , 106264.	1.9	0
709	A blockchain-based framework to support pharmacogenetic data sharing. <i>Pharmacogenomics Journal</i> , 2022, 22, 264-275.	0.9	5
710	Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention. <i>PLoS ONE</i> , 2022, 17, e0272140.	1.1	1
711	Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention. <i>Pharmacogenomics</i> , 2022, 23, 723-737.	0.6	21
712	Pharmacogenetics of Antiplatelet Therapy. <i>Annual Review of Pharmacology and Toxicology</i> , 2023, 63, 211-229.	4.2	9
713	Effects of <i>CYP2C19</i> genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy. <i>Epilepsia</i> , 2022, 63, 2958-2969.	2.6	5
714	<i>CYP2C19</i> polymorphisms and lipoproteins associated with clopidogrel resistance in children with Kawasaki disease in China: A prospective study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
715	The role of <i>CYP2C19</i> genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 811-825.	1.3	6
716	Platelet reactivity after clopidogrel loading in patients with acute ischemic stroke. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	0
718	Association between <i>CYP2C19</i> and <i>CYP2B6</i> phenotypes and the pharmacokinetics and safety of diazepam. <i>Biomedicine and Pharmacotherapy</i> , 2022, 155, 113747.	2.5	8
719	Pharmacogenomics Informs Cardiovascular Pharmacotherapy. <i>Methods in Molecular Biology</i> , 2022, , 201-240.	0.4	0
720	Precision Medicine in Cardiovascular Disease Practice. , 2022, , 53-66.		0
721	Chapter 3: Pharmacogenomics Testing. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
722	Chapter 2: Pharmacogenomics: Drug Exposure and Response. , 2022, , .		0
723	Chapter 1: Foundations of Pharmacogenomics. , 2022, , .		0
724	Effects of ilaprazole on the steady-state pharmacodynamics of clopidogrel in healthy volunteers: An open-label randomized crossover study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
725	Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (<scp>CPIC</scp>) Guidelines: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1318-1328.	2.3	32
726	Impact of integrating genomic data into the electronic health record on genetics care delivery. <i>Genetics in Medicine</i> , 2022, 24, 2338-2350.	1.1	8
727	Recommendations for Clinical Application of Pharmacogenetic Test Results Interpretation by Clinical Laboratories. <i>Laboratory Medicine Online</i> , 2022, 12, 244-261.	0.0	0
728	Therapeutic Drug Monitoring and Toxicology: Relevance of Measuring Metabolites. , 2022, , 197-232.		0
730	Using human genetics to improve safety assessment of therapeutics. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 145-162.	21.5	20
731	Building Evidence for Clinical Use of Pharmacogenomics and Reimbursement for Testing. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 533-546.	0.7	3
732	New Approaches in P2Y12 Receptor Blocker Drugs Use. <i>Frontiers in Cardiovascular Drug Discovery</i> , 2022, , 141-190.	0.0	0
733	CYP2C19 genotype and platelet aggregation test-guided dual antiplatelet therapy after off-pump coronary artery bypass grafting: A retrospective cohort study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
734	Which four medication classes have important pharmacogenetic considerations?. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2023, 36, 12-13.	0.1	0
735	Elective genomic testing: Practice resource of the National Society of Genetic Counselors. <i>Journal of Genetic Counseling</i> , 2023, 32, 281-299.	0.9	3
736	Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease. <i>BMC Cardiovascular Disorders</i> , 2022, 22, .	0.7	4
737	Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety. <i>Pharmaceutics</i> , 2023, 15, 404.	2.0	1
738	A nomogram to predict the risk of bleeding after discharge from stent-assisted ruptured aneurysm embolization in a Chinese population. <i>Neurosurgical Review</i> , 2023, 46, .	1.2	0
740	Pharmacogenomics in Asians: Differences and similarities with other human populations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2023, 19, 27-41.	1.5	11
741	Impact of pharmacogenomics in achieving personalized/precision medicine in the clinical setting: a symposium report. <i>Pharmacogenomics</i> , 2023, 24, 123-129.	0.6	2

#	ARTICLE	IF	CITATIONS
743	CD80 DNA methylation and single-nucleotide polymorphism associated with clopidogrel response: a whole-genome DNA methylation analysis in acute coronary syndrome. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100093.	1.0	0
744	A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China. <i>Journal of Clinical Laboratory Analysis</i> , 2023, 37, .	0.9	6
745	Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease. <i>Nature Communications</i> , 2023, 14, .	5.8	10
746	Comparison of De-escalation of DAPT Intensity or Duration in East Asian and Western Patients with ACS Undergoing PCI: A Systematic Review and Meta-analysis. <i>Thrombosis and Haemostasis</i> , 2023, 123, 773-792.	1.8	8
747	A meta-analysis of cyp2c19 gene testing on the prognosis of patients aged 60 years and older with acute coronary syndrome. , 2023, 2, 20-23.		0
748	A comparison of safety and efficacy between long-term DAPT and intensive statins combined with short-term DAPT for acute ischemic stroke. <i>European Journal of Medical Research</i> , 2023, 28, .	0.9	1
750	Pharmacogenetics and toxicology. , 2024, , 467-491.		0
754	The Implementation of Pharmacogenetics in the United Kingdom. <i>Handbook of Experimental Pharmacology</i> , 2023, , .	0.9	2
756	Genetic Contributions and Personalized Medicine. , 2023, , 3-17.		0
757	Evidence on the Impact of Pharmacogenetics to Treat and Manage Cardiovascular Diseases. , 2023, , 1-49.		0
768	Influence of CYP2C19*2 Polymorphism on Clinical Outcomes in Moldovaâ€™s Patients Treated with Clopidogrel After Percutaneous Coronary Intervention. <i>IFMBE Proceedings</i> , 2024, , 528-536.	0.2	0
773	Evidence on the Impact of Pharmacogenetics to Treat and Manage Cardiovascular Diseases. , 2023, , 638-685.		0
775	Pharmacogenomics in cardiovascular disease. , 2024, , 623-642.		0
780	Pharmacogenomics in Cardiovascular Diseases. , 2023, , 201-237.		0
782	Clinical Genetics and Referrals. , 2024, , 45-72.		0
784	Pharmacogenomics of Drug-Metabolizing Enzymes. , 2023, , 35-60.		0
785	Pharmacogenomics of Drug Safety. , 2023, , 413-437.		0
786	Pharmacogenetic Algorithms. , 2023, , 105-131.		0

#	ARTICLE	IF	CITATIONS
787	Pharmacogenomic Cases: Clopidogrel for Coronary Artery Disease. , 2024, , 503-505.		0
793	Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation. , 2023, , 17-34.		0